How are these compounds
scientifically different?
Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.
This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.
Target & Mechanism Comparison
Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.
← Scroll to see all compounds →
| Target | Thymosin Beta-4 (TB-4) | Thymosin Alpha-1 |
|---|---|---|
| ✓ | — | |
| — | ✓ |
What These Compounds Share
Key Differences
Compound Detail
Thymosin Beta-4 (TB-4)
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
43-amino-acid peptide · 43 amino acids · Synthetic -- third-party analytical testing identifies the tested Vital Edge sample as Thymosin Beta-4 (see Current Vital Edge Testing below); this product-level analytical result is separate from evidence concerning the pharmacology or clinical effects of Thymosin Beta-4, and is not assumed from the commercial name alone
Also known as: TB-500, Tβ4, TB4
Tap a target above for a plain-language explanation.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View Research Sources (2) →
Third-party analytical report (Janoshik) identifies the sample as "TB-500 (TB4)" with a quantified result (10.19 mg) and 99.803% purity. This is identity/purity evidence for what is in this specific product's vial, not clinical or pharmacological evidence about Thymosin Beta-4 as a molecule.
Supports: molecular_type, peptide_length, endogenous_status, canonical_name
Second batch, same product -- included for continuity of identity verification across batches.
Supports: molecular_type, peptide_length, endogenous_status
Thymosin Alpha-1
View in Research Explorer →
Regulatory status and clinical-development history for Thymosin Alpha-1.
Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.
28-amino-acid peptide · 28 amino acids · Endogenous / synthetic analogue in research use
Also known as: Tα1, Thymalfasin
Tap a target above for a plain-language explanation.
Human study (3 formulations, healthy volunteers) reported Tmax approximately 1-2 hours and a short elimination half-life (<3h), with exposure varying by formulation -- not a single fixed value.
Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.
View in Research Explorer →
Regulatory status and clinical-development history for Thymosin Alpha-1.
View Research Sources (1) →
Tmax ~1-2h; short elimination half-life (<3h in this study); exposure varied by formulation.
Supports: human_half_life
Common Research Comparisons
Frequently studied groupings — not recommendations.
Browse more compounds
5-Amino-1MQ
NNMT inhibitor
BPC-157
Gastric pentadecapeptide
Cagrilintide
Long-acting amylin analogue
CJC-1295
Modified GHRH analogue
DSIP
Neuropeptide
Epithalon
Synthetic tetrapeptide
GHK-Cu
Copper-binding tripeptide
GHRP-2
GH-releasing peptide / GH secretagogue
Glutathione
Endogenous antioxidant tripeptide
HCG
Glycoprotein hormone
IGF-1 LR3
IGF-1 receptor agonist (engineered analogue)
Ipamorelin
GH secretagogue
Kisspeptin-10
Kisspeptin fragment
KPV
α-MSH-derived tripeptide
Melanotan I
α-MSH analogue
Melanotan II
Cyclic melanocortin agonist
MOTS-c
Mitochondrial-derived peptide
NAD+
Cellular redox cofactor
PT-141
Cyclic melanocortin receptor agonist
Retatrutide
Triple receptor agonist
rHGH (Somatropin)
Growth hormone receptor agonist
Selank
Synthetic tuftsin analogue
Semaglutide
GLP-1 receptor agonist
Semax
Synthetic ACTH-fragment analogue
Sermorelin
GHRH fragment analogue
SS-31
Mitochondria-targeting tetrapeptide
Tesamorelin
Stabilised GHRH analogue
Thymosin Alpha-1
Thymic peptide
Thymosin Beta-4 (TB-4)
Thymosin Beta-4
Tirzepatide
Dual incretin receptor agonist